{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:39Z","timestamp":1777564359317,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OCAY-13\u2013309"],"award-info":[{"award-number":["OCAY-13\u2013309"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semarthrit.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T07:11:19Z","timestamp":1519197079000},"page":"293-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Lisa","family":"Stamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie B.","family":"Morillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Lassere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2018.02.009_bib1","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.02.009_bib4","first-page":"58","article-title":"Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib5","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricaemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricaemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.02.009_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib9","series-title":"Clinical measurement in drug evaluation, in a regulatory authority\u2019s opinion about surrogate endpoints","first-page":"3","author":"Temple","year":"1995"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","article-title":"Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop","volume":"22","author":"De Gruttola","year":"2001","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.02.009_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2010.09.003","article-title":"Serum urate as a soluble biomarker in chronic gout\u2014evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers","volume":"40","author":"Stamp","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-12-27","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"e012026","DOI":"10.1136\/bmjopen-2016-012026","article-title":"Using serum urate as a validated surrogate endpoint for flares in patients with gout: protocol for a systematic review and meta-regression analysis","volume":"6","author":"Morillon","year":"2016","journal-title":"BMJ open"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.02.009_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11 Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.02.009_bib18","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.02.009_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat Meth Med Res"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib20","unstructured":"Lassere, M, The innovative evaluation schema of validating putative surrogate endpoints, in Joint Statistical Meeting. 2010: Vancouver, Canada."},{"key":"10.1016\/j.semarthrit.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/annonc\/mdu267","article-title":"Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review","volume":"26","author":"Johnson","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib22","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia","volume":"37","author":"Fraser","year":"1987","journal-title":"J R Coll Gen Pract"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the healthrelated quality of life: short form-36 is responsive qto change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.02.009_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2105\/AJPH.72.12.1336","article-title":"Uses of ecological analysis in epidemiologic research","volume":"72","author":"Morgenstern","year":"1982","journal-title":"Am J Pub Health"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.02.009_bib27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.02.009_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","article-title":"Cellular characterization of the gouty tophus: a quantitative analysis","volume":"62","author":"Dalbeth","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.02.009_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Care Res"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/annrheumdis-2017-eular.5006","article-title":"Nurse-led care versus general practitioner care of people with gout: a UK community-based randomised controlled trial","volume":"76","author":"Doherty","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib36","unstructured":"Federal Drug Administration, 2016. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/ucm535922.htm"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.2007.079970","article-title":"A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout","volume":"67","author":"Taylor","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib38","article-title":"Variability in the reporting of serum urate and flares in gout clinical trials: need for minimal reporting requirements","author":"Stamp","year":"2017","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2018.02.009_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2017-eular.3219","article-title":"Validation of a definition for attack (FLARE) in patients with established gout","volume":"76","author":"Gaffo","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.02.009_bib40","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of a flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","article-title":"An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia","volume":"17","author":"Huang","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.02.009_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib43","first-page":"1","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B\u204e5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.02.009_bib45","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to convenional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.semarthrit.2018.02.009_bib47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"}],"updated-by":[{"DOI":"10.1016\/j.semarthrit.2023.152255","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000}}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217306297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217306297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:52:47Z","timestamp":1751410367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217306297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0049017217306297"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.009","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.semarthrit.2023.152255","asserted-by":"object"}]},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}